NCT03591510 2026-03-13
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
Novartis
Phase 2 Active not recruiting
Novartis
Institute of Hematology & Blood Diseases Hospital, China
H. Lee Moffitt Cancer Center and Research Institute
St. Jude Children's Research Hospital